Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

Who May Qualify: - Adult patients, and minor patients ≥ 2 years old diagnosed with LGS, DS or TSC. - Clinical decision, taken by the physician, to initiate Epidyolex® - Adult participants, parents or legal representatives must be willing and able to give willing to sign a consent form/assent for participation in the study. Who Should NOT Join This Trial: - Participants currently using or have used recreational, medicinal cannabis, or cannabinoid-based products within the three months prior to study entry and are unwilling to abstain from these products for the duration of the study. - Any reason, according to Investigator's judgment, able to compromise compliance with procedures outlined in the study There will not be any other specific exclusion criteria; however, contraindications, special warnings, and precautions for use as detailed in the Summary of Product Characteristics (SmPC) (particularly related to raising of aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], and total bilirubin) will have to be considered by the treating physician. Always talk to your doctor about whether this trial is right for you.